{"id":"W3005336040","doi":"10.1200/jco.19.02044","title":"EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Wnt/β-catenin signaling in development and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":327,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation; Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Jounce Therapeutics; AstraZeneca; Bristol-Myers Squibb; Mirati Therapeutics; Syndax Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Astellas Pharma; Genentech; INOVIO Pharmaceuticals","keywords":"Medicine; Tolerability; Internal medicine; Adverse effect; Rash; Nausea; Oncology; Regimen; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Phases of clinical research; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001101807,0.001098639,0.001163336,0.0002878832,0.0003767601,0.0008689827,0.0006613759,0.0009300604,0.001951755],"category_scores_gemma":[0.0005818165,0.0006123512,0.0008317973,0.000295542,0.0006653015,0.0007478177,0.0002862009,0.002585857,0.000599956],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009592131,"about_ca_system_score_gemma":0.001607666,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005837629,"about_ca_topic_score_gemma":0.002355201,"domain_scores_codex":[0.9997496,0.0001000606,0.00001607004,0.00004630549,0.00003194654,0.0000559708],"domain_scores_gemma":[0.9995877,0.00005773952,0.00007065568,0.00003983436,0.00002965734,0.000214385],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3397443,0.1769355,0.03040205,0.001913757,0.002144335,0.001182583,0.0008148623,0.01010159,0.1993556,0.0007111824,0.005464066,0.2312302],"study_design_scores_gemma":[0.2868263,0.659505,0.02410883,0.00007387682,0.0005917695,0.001548771,0.0001716716,0.00343156,0.01667486,0.0002828056,0.006726443,0.00005816825],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960287,0.001130003,0.0003521411,0.0001730819,0.00004902051,0.001023654,0.0002829482,0.00004665327,0.0009137683],"genre_scores_gemma":[0.9948769,0.0009331898,0.0009775438,0.0003924257,0.00004411591,0.0008046764,0.0008401773,0.00001387086,0.001117065],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001951755,"threshold_uncertainty_score":0.006959617,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1093500930747905,"score_gpt":0.4089754387298743,"score_spread":0.2996253456550838,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}